Loading…
Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter
Summary Background The safety and survival benefit of transcatheter arterial chemoembolization for patients with huge hepatocellular carcinoma is uncertain. Aim To evaluate the role of embolization in unresectable hepatocellular carcinomas larger than 10 cm. Methods Twenty‐six consecutive patients w...
Saved in:
| Published in: | Alimentary pharmacology & therapeutics 2006-01, Vol.23 (1), p.129-135 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4474-27a760ae7ff5488d4d1cf5fe108a59aad6bad6a2e6b890c3f447c4d6340c5c213 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4474-27a760ae7ff5488d4d1cf5fe108a59aad6bad6a2e6b890c3f447c4d6340c5c213 |
| container_end_page | 135 |
| container_issue | 1 |
| container_start_page | 129 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 23 |
| creator | HUANG, Y.‐H. WU, J.‐C. CHEN, S.‐C. CHEN, C.‐H. CHIANG, J.‐H. HUO, T.‐I. LEE, P.‐C. CHANG, F.‐Y. LEE, S.‐D. |
| description | Summary
Background
The safety and survival benefit of transcatheter arterial chemoembolization for patients with huge hepatocellular carcinoma is uncertain.
Aim
To evaluate the role of embolization in unresectable hepatocellular carcinomas larger than 10 cm.
Methods
Twenty‐six consecutive patients who had an unresectable hepatocellular carcinoma larger than 10 cm and refused aggressive treatment, were enrolled as the control group. Another 31 patients matching with the control cases and undergoing embolization for huge unresectable hepatocellular carcinoma served as the embolization group. Survival between the two groups was compared.
Results
Two patients (7%) died from embolization‐related complications. Patients in embolization group had longer survival than those in control group (median survival: 9.13 vs. 2.1 months). The 1‐, 3‐ and 5‐year survival rates in embolization group were 42%, 13% and 7% respectively. The 1‐ and 3‐year survival rates for patients in control group were 8% and 0% respectively. In multivariate analysis, embolization and prothrombin ratio ≤1.2 were two independent factors associated with a better survival.
Conclusions
Embolization‐related mortality is low for huge hepatocellular carcinoma, and the technique provides survival benefit in patients with unresectable hepatocellular carcinomas larger than 10 cm in diameter. |
| doi_str_mv | 10.1111/j.1365-2036.2006.02704.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67604583</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67604583</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4474-27a760ae7ff5488d4d1cf5fe108a59aad6bad6a2e6b890c3f447c4d6340c5c213</originalsourceid><addsrcrecordid>eNqNkc2O1SAUx4lx4lxHX8Gw0V0rBQrtwsVkoqPJJJo4rskpBctNW65A52s1ySQ-qE8i9d442yEBzgm_88H_IIQrUlZ5vd-WFRN1QQkTJSVElIRKwsubZ2jz_-E52hAq2oI2FTtGL2PckkxKQl-g40qwltGWbNDv70u4clcw4s7MxrqEvcUpwBw1pMEkEzCEfLpM6MFM3kydH90dJOdn7Ga8y5aZU8TXLg14MNn32ozjMkLAGoJ2s58AZ-9nzpUGmPMv_tw_6GmN7h1Ma5FX6MjCGM3rw32Cfnz6eHn2ubj4ev7l7PSi0JxLXlAJUhAw0tqaN03P-0rb2pqKNFC3AL3o8gZqRNe0RDObozTvBeNE15pW7AS92-fdBf9rMTGpycW1XZiNX6ISOT2vG5bBZg_q4GMMxqpdcBOEW1URtc5AbdUqtVqlVusM1L8ZqJsc-uZQY-km0z8GHkTPwNsDAFnl0Wa1tYuPnOSyYbLO3Ic9d-1Gc_vkBtTpt8vVYn8BNjumUQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67604583</pqid></control><display><type>article</type><title>Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter</title><source>Wiley</source><creator>HUANG, Y.‐H. ; WU, J.‐C. ; CHEN, S.‐C. ; CHEN, C.‐H. ; CHIANG, J.‐H. ; HUO, T.‐I. ; LEE, P.‐C. ; CHANG, F.‐Y. ; LEE, S.‐D.</creator><creatorcontrib>HUANG, Y.‐H. ; WU, J.‐C. ; CHEN, S.‐C. ; CHEN, C.‐H. ; CHIANG, J.‐H. ; HUO, T.‐I. ; LEE, P.‐C. ; CHANG, F.‐Y. ; LEE, S.‐D.</creatorcontrib><description>Summary
Background
The safety and survival benefit of transcatheter arterial chemoembolization for patients with huge hepatocellular carcinoma is uncertain.
Aim
To evaluate the role of embolization in unresectable hepatocellular carcinomas larger than 10 cm.
Methods
Twenty‐six consecutive patients who had an unresectable hepatocellular carcinoma larger than 10 cm and refused aggressive treatment, were enrolled as the control group. Another 31 patients matching with the control cases and undergoing embolization for huge unresectable hepatocellular carcinoma served as the embolization group. Survival between the two groups was compared.
Results
Two patients (7%) died from embolization‐related complications. Patients in embolization group had longer survival than those in control group (median survival: 9.13 vs. 2.1 months). The 1‐, 3‐ and 5‐year survival rates in embolization group were 42%, 13% and 7% respectively. The 1‐ and 3‐year survival rates for patients in control group were 8% and 0% respectively. In multivariate analysis, embolization and prothrombin ratio ≤1.2 were two independent factors associated with a better survival.
Conclusions
Embolization‐related mortality is low for huge hepatocellular carcinoma, and the technique provides survival benefit in patients with unresectable hepatocellular carcinomas larger than 10 cm in diameter.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2006.02704.x</identifier><identifier>PMID: 16393290</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Science Ltd</publisher><subject>Adult ; Aged ; Biological and medical sciences ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - therapy ; Case-Control Studies ; Catheterization - methods ; Chemoembolization, Therapeutic - methods ; Digestive system ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Liver Neoplasms - pathology ; Liver Neoplasms - therapy ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Pharmacology. Drug treatments ; Retrospective Studies ; Survival Analysis ; Tumors</subject><ispartof>Alimentary pharmacology & therapeutics, 2006-01, Vol.23 (1), p.129-135</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4474-27a760ae7ff5488d4d1cf5fe108a59aad6bad6a2e6b890c3f447c4d6340c5c213</citedby><cites>FETCH-LOGICAL-c4474-27a760ae7ff5488d4d1cf5fe108a59aad6bad6a2e6b890c3f447c4d6340c5c213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17478375$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16393290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HUANG, Y.‐H.</creatorcontrib><creatorcontrib>WU, J.‐C.</creatorcontrib><creatorcontrib>CHEN, S.‐C.</creatorcontrib><creatorcontrib>CHEN, C.‐H.</creatorcontrib><creatorcontrib>CHIANG, J.‐H.</creatorcontrib><creatorcontrib>HUO, T.‐I.</creatorcontrib><creatorcontrib>LEE, P.‐C.</creatorcontrib><creatorcontrib>CHANG, F.‐Y.</creatorcontrib><creatorcontrib>LEE, S.‐D.</creatorcontrib><title>Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary
Background
The safety and survival benefit of transcatheter arterial chemoembolization for patients with huge hepatocellular carcinoma is uncertain.
Aim
To evaluate the role of embolization in unresectable hepatocellular carcinomas larger than 10 cm.
Methods
Twenty‐six consecutive patients who had an unresectable hepatocellular carcinoma larger than 10 cm and refused aggressive treatment, were enrolled as the control group. Another 31 patients matching with the control cases and undergoing embolization for huge unresectable hepatocellular carcinoma served as the embolization group. Survival between the two groups was compared.
Results
Two patients (7%) died from embolization‐related complications. Patients in embolization group had longer survival than those in control group (median survival: 9.13 vs. 2.1 months). The 1‐, 3‐ and 5‐year survival rates in embolization group were 42%, 13% and 7% respectively. The 1‐ and 3‐year survival rates for patients in control group were 8% and 0% respectively. In multivariate analysis, embolization and prothrombin ratio ≤1.2 were two independent factors associated with a better survival.
Conclusions
Embolization‐related mortality is low for huge hepatocellular carcinoma, and the technique provides survival benefit in patients with unresectable hepatocellular carcinomas larger than 10 cm in diameter.</description><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Case-Control Studies</subject><subject>Catheterization - methods</subject><subject>Chemoembolization, Therapeutic - methods</subject><subject>Digestive system</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - therapy</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Pharmacology. Drug treatments</subject><subject>Retrospective Studies</subject><subject>Survival Analysis</subject><subject>Tumors</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqNkc2O1SAUx4lx4lxHX8Gw0V0rBQrtwsVkoqPJJJo4rskpBctNW65A52s1ySQ-qE8i9d442yEBzgm_88H_IIQrUlZ5vd-WFRN1QQkTJSVElIRKwsubZ2jz_-E52hAq2oI2FTtGL2PckkxKQl-g40qwltGWbNDv70u4clcw4s7MxrqEvcUpwBw1pMEkEzCEfLpM6MFM3kydH90dJOdn7Ga8y5aZU8TXLg14MNn32ozjMkLAGoJ2s58AZ-9nzpUGmPMv_tw_6GmN7h1Ma5FX6MjCGM3rw32Cfnz6eHn2ubj4ev7l7PSi0JxLXlAJUhAw0tqaN03P-0rb2pqKNFC3AL3o8gZqRNe0RDObozTvBeNE15pW7AS92-fdBf9rMTGpycW1XZiNX6ISOT2vG5bBZg_q4GMMxqpdcBOEW1URtc5AbdUqtVqlVusM1L8ZqJsc-uZQY-km0z8GHkTPwNsDAFnl0Wa1tYuPnOSyYbLO3Ic9d-1Gc_vkBtTpt8vVYn8BNjumUQ</recordid><startdate>200601</startdate><enddate>200601</enddate><creator>HUANG, Y.‐H.</creator><creator>WU, J.‐C.</creator><creator>CHEN, S.‐C.</creator><creator>CHEN, C.‐H.</creator><creator>CHIANG, J.‐H.</creator><creator>HUO, T.‐I.</creator><creator>LEE, P.‐C.</creator><creator>CHANG, F.‐Y.</creator><creator>LEE, S.‐D.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200601</creationdate><title>Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter</title><author>HUANG, Y.‐H. ; WU, J.‐C. ; CHEN, S.‐C. ; CHEN, C.‐H. ; CHIANG, J.‐H. ; HUO, T.‐I. ; LEE, P.‐C. ; CHANG, F.‐Y. ; LEE, S.‐D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4474-27a760ae7ff5488d4d1cf5fe108a59aad6bad6a2e6b890c3f447c4d6340c5c213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Case-Control Studies</topic><topic>Catheterization - methods</topic><topic>Chemoembolization, Therapeutic - methods</topic><topic>Digestive system</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - therapy</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Pharmacology. Drug treatments</topic><topic>Retrospective Studies</topic><topic>Survival Analysis</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HUANG, Y.‐H.</creatorcontrib><creatorcontrib>WU, J.‐C.</creatorcontrib><creatorcontrib>CHEN, S.‐C.</creatorcontrib><creatorcontrib>CHEN, C.‐H.</creatorcontrib><creatorcontrib>CHIANG, J.‐H.</creatorcontrib><creatorcontrib>HUO, T.‐I.</creatorcontrib><creatorcontrib>LEE, P.‐C.</creatorcontrib><creatorcontrib>CHANG, F.‐Y.</creatorcontrib><creatorcontrib>LEE, S.‐D.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HUANG, Y.‐H.</au><au>WU, J.‐C.</au><au>CHEN, S.‐C.</au><au>CHEN, C.‐H.</au><au>CHIANG, J.‐H.</au><au>HUO, T.‐I.</au><au>LEE, P.‐C.</au><au>CHANG, F.‐Y.</au><au>LEE, S.‐D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2006-01</date><risdate>2006</risdate><volume>23</volume><issue>1</issue><spage>129</spage><epage>135</epage><pages>129-135</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Summary
Background
The safety and survival benefit of transcatheter arterial chemoembolization for patients with huge hepatocellular carcinoma is uncertain.
Aim
To evaluate the role of embolization in unresectable hepatocellular carcinomas larger than 10 cm.
Methods
Twenty‐six consecutive patients who had an unresectable hepatocellular carcinoma larger than 10 cm and refused aggressive treatment, were enrolled as the control group. Another 31 patients matching with the control cases and undergoing embolization for huge unresectable hepatocellular carcinoma served as the embolization group. Survival between the two groups was compared.
Results
Two patients (7%) died from embolization‐related complications. Patients in embolization group had longer survival than those in control group (median survival: 9.13 vs. 2.1 months). The 1‐, 3‐ and 5‐year survival rates in embolization group were 42%, 13% and 7% respectively. The 1‐ and 3‐year survival rates for patients in control group were 8% and 0% respectively. In multivariate analysis, embolization and prothrombin ratio ≤1.2 were two independent factors associated with a better survival.
Conclusions
Embolization‐related mortality is low for huge hepatocellular carcinoma, and the technique provides survival benefit in patients with unresectable hepatocellular carcinomas larger than 10 cm in diameter.</abstract><cop>Oxford, UK</cop><pub>Blackwell Science Ltd</pub><pmid>16393290</pmid><doi>10.1111/j.1365-2036.2006.02704.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2006-01, Vol.23 (1), p.129-135 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67604583 |
| source | Wiley |
| subjects | Adult Aged Biological and medical sciences Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Case-Control Studies Catheterization - methods Chemoembolization, Therapeutic - methods Digestive system Female Gastroenterology. Liver. Pancreas. Abdomen Humans Liver Neoplasms - pathology Liver Neoplasms - therapy Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Multivariate Analysis Pharmacology. Drug treatments Retrospective Studies Survival Analysis Tumors |
| title | Survival benefit of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma larger than 10 cm in diameter |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T14%3A49%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20benefit%20of%20transcatheter%20arterial%20chemoembolization%20in%20patients%20with%20hepatocellular%20carcinoma%20larger%20than%2010%E2%80%83cm%20in%20diameter&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=HUANG,%20Y.%E2%80%90H.&rft.date=2006-01&rft.volume=23&rft.issue=1&rft.spage=129&rft.epage=135&rft.pages=129-135&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2006.02704.x&rft_dat=%3Cproquest_cross%3E67604583%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4474-27a760ae7ff5488d4d1cf5fe108a59aad6bad6a2e6b890c3f447c4d6340c5c213%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67604583&rft_id=info:pmid/16393290&rfr_iscdi=true |